Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/18480| Title: | Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness. | Austin Authors: | Harrington, Karra D;Lim, Yen Ying;Ames, David;Hassenstab, Jason;Laws, Simon M;Martins, Ralph N;Rainey-Smith, Stephanie R;Robertson, Joanne;Rowe, Christopher C ;Salvado, Olivier;Doré, Vincent ;Villemagne, Victor L ;Snyder, Peter J;Masters, Colin L ;Maruff, Paul | Affiliation: | School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia, Australia, Australia Department of Psychological & Brain Sciences, Washington University, St. Louis, MO, USA The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia National Ageing Research Institute, Parkville, Victoria, Australia CogState Ltd., Melbourne, Victoria, Australia CSIRO Health and Biosecurity, The Australian eHealth Research Centre, Brisbane, Queensland, Australia Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia, Australia Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA Department of Molecular Imaging, Austin Health, Heidelberg, Victoria, Australia, Australia |
Issue Date: | 2017 | Date: | 2017 | Publication information: | Alzheimer's & dementia (Amsterdam, Netherlands) 2017; 8: 156-164 | Abstract: | INTRODUCTION: High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. METHOD: Cognition was measured over 72 months and compared between low (Aβ-) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. RESULTS: Compared to the Aβ- group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. DISCUSSION: Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/18480 | DOI: | 10.1016/j.dadm.2017.05.006 | ORCID: | 0000-0003-3910-2453 | Journal: | Alzheimer's & dementia (Amsterdam, Netherlands) | PubMed URL: | 28761926 | ISSN: | 2352-8729 | Type: | Journal Article | Subjects: | Alzheimer disease Amyloid Cognitive aging Memory Normal aging |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.